Status:
COMPLETED
Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)
Lead Sponsor:
Yonsei University
Conditions:
Small Abdominal Aortic Aneurysm
Eligibility:
All Genders
20-90 years
Phase:
PHASE4
Brief Summary
Various medical therapies have been proposed to prevent abdominal aortic aneurysm expansion. However, there have been very few randomized clinical trials to support use of any of these treatments. Sev...
Eligibility Criteria
Inclusion
- Age ≥20years
- Abdominal aortic aneurysm with maximal diameter less than 5cm
- Hypertension
- Patient with signed informed consent
Exclusion
- Saccular type aneurysm, inflammatory aneurysm, or infected aneurysm
- Aortic dissection
- Planned surgery or endovascular therapy for abdominal aortic aneurysm within 1 year
- Previous aorta surgery or endovascular therapy
- Contraindications to Beta-blocker or ARB (allergic reactions, asthma, severe bradycardia, angioedema, hyperkalemia)
- Allergic reaction to contrast dye
- Known genetic aorta disease or autoimmune or connective tissue disease: Marfan syndrome, Shprintzen-Goldberg syndrome, Loeys-Dietz syndrome, Takayasu's arteritis, Behcet's disease
- Pregnancy
- Life expectation \<1 year
- Renal failure (serum Cr \>2.0 mg/dL)
- Liver disease (ALT or AST \> 3 x upper limit) or liver cirrhosis (Child B or C)
- Malignancy requiring surgery or chemotherapy within 1 year after enrollment
- Status post transplantation or chronic inflammatory disease requiring immune suppressive drugs over 4 weeks
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2017
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01904981
Start Date
January 1 2014
End Date
April 18 2017
Last Update
March 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, South Korea, 120-752